Last updated: July 28, 2026
Theophylline in Dextrose 5% In Plastic Container: Clinical Trials Update, Market Size, Pricing and Revenue Projections
Theophylline in dextrose 5% in a plastic container is an IV formulation used for bronchospasm in settings where oral therapy is not feasible. Public, sponsor-level clinical-trial updates and market forecasts for this exact dosage form are typically not published as a standalone product in major registries; market behavior is driven primarily by (1) generic IV theophylline competition and (2) hospital uptake of IV methylxanthines. For forward-looking planning, the usable commercial view is therefore the blended exposure of IV theophylline products, constrained by shortages/discontinuations and payer-driven generic selection.
What clinical trials exist for IV theophylline in dextrose 5% plastic containers, and what is the latest update?
Featured snippet answer: No widely indexed, product-specific late-stage trials are consistently reported for “theophylline in dextrose 5% in plastic container” as a distinct formulation across ClinicalTrials.gov records; clinical evidence is dominated by older theophylline IV studies and general theophylline pharmacokinetics.
What drug entity do most trials target, and why does the formulation name matter less?
Most interventional work around theophylline focuses on:
- IV-to-oral conversion, loading/maintenance strategies, and bronchodilator efficacy.
- Therapeutic drug monitoring and toxicity mitigation because of narrow therapeutic index risk.
For IV trials, sponsors often list “theophylline” without granular container and diluent specifics. The dextrose 5% carrier and plastic container impact administration logistics and compatibility more than clinical endpoints.
What endpoints show up in theophylline IV studies?
Typical endpoints include:
- Change in FEV1 or symptom scores in asthma/COPD bronchospasm
- Time to bronchodilation response
- Serum theophylline concentration vs target range (therapeutic monitoring)
- Incidence of adverse events (nausea, tremor, arrhythmia), with concentration-response analysis
What would count as a meaningful “latest update” for this product?
In practice, “latest update” for this exact IV presentation is usually reflected by:
- Regulatory listing changes (discontinuations, supplements, labeling revisions)
- Shortage announcements that affect supply and net price realization
- Conducted-but-not-public product bridging studies for generic equivalence (often not posted as interventional trials)
No current interventional development signal can be asserted for this exact formulation name without reliable, product-specific trial indexing.
What is the Orange Book status of theophylline IV products, and which patents protect the active ingredient vs the formulation?
Featured snippet answer: Patent protection for IV theophylline is generally limited by time. Theophylline is an older small-molecule bronchodilator; most protection now comes from expiring process, formulation, or method-of-use claims rather than composition-of-matter. Orange Book status must be checked per NDC because historical listings can persist even when patents are expired.
How to map “theophylline in dextrose 5% in plastic container” to Orange Book records
Orange Book listings are keyed to:
- Drug product active ingredient strength and dosage form
- Applicant/labeler
- Patent numbers tied to that specific NDA/ANDA label
For hospital purchasing, the formulation’s clinical identity tracks the active ingredient and route more than container material. Container and diluent can affect stability and labeling, which can map to supplement patents.
What patent types are most commonly seen for legacy IV solutions?
Where patents remain, they tend to be:
- Formulation or stability-related patents tied to storage conditions and shelf-life
- Method-of-manufacture patents (mixing, filtration, sterilization parameters)
- Packaging-related claims (less common than formulation/process for generics)
- Method-of-use patents are less common for theophylline given long-standing indications, but can appear for specific dosing algorithms or therapeutic monitoring programs
When do generics or authorized equivalents lose exclusivity, and what is the likely generic entry timing path?
Featured snippet answer: For theophylline IV solutions, exclusivity and patent barriers are typically already expired; current competition is driven by manufacturing capacity, supply reliability, and generic substitution rather than new exclusivity windows.
What timing usually governs market entry for IV theophylline?
The entry path is usually:
- ANDA approval to a reference NDA
- Stability/compatibility studies and label updates
- Ongoing manufacturing continuity and compliance performance
- Supply contracts and hospital formulary adoption
What can still delay or shape entry even with expired IP?
Even without active patents, delays happen due to:
- Sterile manufacturing line availability
- Bulk theophylline sourcing continuity
- Quality events leading to site remediation
- Shortage-related constraints that temporarily support higher net prices for remaining suppliers
What market size and demand drives revenue for IV theophylline solutions?
Featured snippet answer: Demand is modest relative to modern inhaled bronchodilators and is concentrated in acute-care and specialty hospital settings. Revenue is highly sensitive to substitution patterns and supply disruptions.
Who buys IV theophylline?
- Hospital pharmacies
- Contract purchasing organizations
- Emergency departments and inpatient respiratory units
- Specialty inpatient respiratory care
What is the demand driver in clinical practice?
Key drivers:
- Inability to take oral medications during acute exacerbations
- Need for rapid bronchodilation while awaiting inhaled therapy escalation
- Therapeutic drug monitoring workflows that make IV theophylline feasible
What competes with IV theophylline?
Therapy substitutes and protocol alternatives include:
- IV and nebulized beta-agonists, anticholinergics
- Systemic corticosteroids (for asthma/COPD exacerbations)
- IV aminophylline in some settings (pharmacologically linked to theophylline, sometimes with different prescribing habits)
Pricing and gross margin: how does IV theophylline trade versus substitutes?
Featured snippet answer: Generic IV theophylline pricing typically compresses versus branded alternatives when multiple suppliers are active; margin shifts track shortage intensity and contracting.
What pricing model dominates in hospital procurement?
- GPO/contract pricing
- Formulary tiering and automatic substitution rules
- Shortage-driven exceptions that can widen price spreads
What supply conditions move net price up or down?
Net pricing tends to rise when:
- 1-2 suppliers remain in a constrained market
- Facilities report allocation or backorders
- Healthcare systems prioritize continuity over cost
Net pricing tends to fall when:
- Additional ANDA approvals ramp production
- Multiple equivalent SKUs normalize distribution
Revenue projection model for theophylline in dextrose 5% IV (plastic container)
Featured snippet answer: For IV theophylline, a defensible projection framework uses (1) treated-patient volume proxy tied to acute-care bronchospasm caseloads, (2) formulary share among IV theophylline and aminophylline options, and (3) net-price trajectory driven by number of active suppliers and shortage status. Public data often lacks product-level granularity, so projections must be anchored to the broader IV theophylline category.
Projection drivers to include in a workable forecast
- Supply status
- Active supplier count and production stability
- Any shortage occurrences
- Competitive substitutions
- Aminophylline uptake
- Increased reliance on inhaled bronchodilator-first protocols
- Contracting cycles
- Annual renewal effects
- GPO changes
- Clinical safety monitoring constraints
- Therapeutic drug monitoring capacity
- Shifts in clinician comfort given narrow therapeutic window
What is the typical projection shape?
- Flat to slowly declining base demand due to chronic management trends favoring inhaled therapies.
- Potential volatility around supply constraints.
- Price declines during multi-supplier ramp-ups; price rebounds during shortages.
A numeric projection cannot be responsibly provided without verifiable, product-specific historical sales and supplier/shortage timeline data for this exact formulation.
Which companies supply IV theophylline solutions, and what is the competitive landscape?
Featured snippet answer: The competitive landscape is usually dominated by generic manufacturers of IV theophylline solutions with label-equivalent presentations. The key differentiator is sterile manufacturing capacity and supply reliability.
What distinguishes suppliers in practice?
- Portfolio breadth across IV bronchodilators
- Sterile fill-finish line uptime
- Stability of distribution
- Contracting relationships with large health systems
What risk exists for investors or licensors?
- Single-site manufacturing concentration raising disruption risk
- Quality remediation leading to temporary capacity loss
- Rapid price erosion after competitor capacity returns
How strong is the IP estate for theophylline IV formulations?
Featured snippet answer: IP strength is generally low for new entrants because theophylline is old; enforceable value is more likely to be in narrow, remaining formulation/process patents than broad composition-of-matter claims.
What patent categories could still matter commercially?
- Stability and shelf-life for specific packaging and diluent combinations
- Manufacturing process improvements tied to impurity profiles
- Specific dosing regimens or therapeutic monitoring methods (less common)
What is litigation risk profile?
For older generics, litigation risk concentrates around:
- ANDA certification disputes tied to any residual patents
- Settlement-triggered “launch blockers” that last only as long as interim agreements
- Administrative exclusivity effects if a newer applicant obtained a later supplementary approval path
Without patent and litigation docket visibility specific to this NDC/presentation, no quantified litigation posture can be stated.
What generic entry risks exist for theophylline IV in dextrose 5% plastic container?
Featured snippet answer: Entry risk is typically manufacturing and regulatory execution rather than IP. The dominant barriers are sterile supply chain reliability and proof of equivalence for the exact dosage form and labeling.
What typically blocks a launch?
- Stability testing for the exact container closure system
- Compatibility labeling with common co-administered IV therapies
- Filling and sterilization capacity constraints
- QC documentation and batch release throughput
What FDA regulatory status applies to this specific IV presentation?
Featured snippet answer: Regulatory status must be checked per NDA/ANDA and NDC. For legacy IV theophylline, most products are approved generics with periodic labeling updates rather than active novel regulatory programs.
What to check on FDA databases for this exact product
- Active ingredient and strength
- Dosage form and route
- Distributor/labeler
- Application type (ANDA vs NDA)
- Supplement history (labeling, stability, manufacturing changes)
- Any current shortages affecting supply
Key Takeaways
- Product-level clinical-trials updates for “theophylline in dextrose 5% in plastic container” are typically not indexed as standalone late-stage programs; the evidence base is mostly older and formulation-neutral beyond IV dosing and monitoring.
- Market demand concentrates in acute-care bronchospasm settings and is sensitive to hospital protocol substitution and supply reliability.
- Patent and exclusivity barriers for IV theophylline are generally limited due to the molecule’s age; competitive dynamics are more often driven by manufacturing capacity and shortage status than active IP.
- Reliable revenue projections require historical product sales and supplier/shortage timelines; without verifiable product-level sales and regulator listing data, only a driver-based projection framework is supportable.
FAQs
- Is IV theophylline still used in asthma and COPD exacerbations, and how does it compare with IV aminophylline?
- What hospital factors increase adoption of IV theophylline over inhaled bronchodilator escalation?
- How do shortages and sterile manufacturing constraints typically affect net pricing for generic IV solutions?
- What Orange Book listings should be reviewed for a specific IV theophylline NDC to map remaining patents?
- What stability and compatibility issues are most important for IV theophylline in dextrose 5% container systems?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026).
- ClinicalTrials.gov. Search results for theophylline (IV) studies. (Accessed 2026).
